Martinez-Garcia Elena, Coll-de la Rubia Eva, Lesur Antoine, Dittmar Gunnar, Gil-Moreno Antonio, Cabrera Silvia, Colas Eva
Proteomics of Cellular Signaling, Department of Infection and Immunity, Luxembourg Institute of Health, 1445 Strassen, Luxembourg.
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, 08035 Barcelona, Spain.
Cancers (Basel). 2023 Jan 31;15(3):911. doi: 10.3390/cancers15030911.
Abnormal uterine bleeding is the main symptom of endometrial cancer (EC), but it is highly nonspecific. This represents a huge burden for women's health since all women presenting with bleeding will undergo sequential invasive tests, which are avoidable for 90-95% of those women who do not have EC.
This study aimed to evaluate the potential of cervical samples collected with five different devices as a source of protein biomarkers to diagnose EC. We evaluated the protein quantity and the proteome composition of five cervical sampling methods.
Samples collected with a Rovers Cervex Brush and the HC2 DNA collection device, Digene, were the most suitable samples for EC proteomic studies. Most proteins found in uterine fluids were also detected in both cervical samples. We then conducted a clinical retrospective study to assess the expression of 52 EC-related proteins in 41 patients (22 EC; 19 non-EC), using targeted proteomics. We identified SERPINH1, VIM, TAGLN, PPIA, CSE1L, and CTNNB1 as potential protein biomarkers to discriminate between EC and symptomatic non-EC women with abnormal uterine bleeding in cervical fluids (AUC > 0.8).
This study opens an avenue for developing non-invasive protein-based EC diagnostic tests, which will improve the standard of care for gynecological patients.
异常子宫出血是子宫内膜癌(EC)的主要症状,但具有高度非特异性。这给女性健康带来了巨大负担,因为所有出现出血症状的女性都要接受一系列侵入性检查,而对于90 - 95%没有患子宫内膜癌的女性来说,这些检查是可以避免的。
本研究旨在评估用五种不同设备采集的宫颈样本作为诊断子宫内膜癌的蛋白质生物标志物来源的潜力。我们评估了五种宫颈采样方法的蛋白质数量和蛋白质组组成。
用Rovers Cervex Brush和Digene的HC2 DNA采集设备采集的样本是最适合进行子宫内膜癌蛋白质组学研究的样本。在子宫液中发现的大多数蛋白质在这两种宫颈样本中也都能检测到。然后,我们进行了一项临床回顾性研究,使用靶向蛋白质组学评估41例患者(22例子宫内膜癌患者;19例非子宫内膜癌患者)中52种与子宫内膜癌相关蛋白质的表达。我们确定丝氨酸蛋白酶抑制剂H1(SERPINH1)、波形蛋白(VIM)、原肌球蛋白(TAGLN)、肽基脯氨酰异构酶A(PPIA)、染色体分离维持蛋白1(CSE1L)和β-连环蛋白(CTNNB1)作为潜在的蛋白质生物标志物,用于区分宫颈液中患有子宫内膜癌和有异常子宫出血症状的非子宫内膜癌女性(曲线下面积>0.8)。
本研究为开发基于蛋白质的非侵入性子宫内膜癌诊断测试开辟了一条途径,这将提高妇科患者的护理标准。